Forecast & RatingOnly 1 analyst currently covers Matinas Biopharma (MTNB.US), with a price target of $30.00 and a rating of "Hold". The sample is very small, so treat this as a reference only. Data as of Jan 6, 2026; this does not constitute investment advice.
Apr 30, 2025Price forecast
$30.0015284.62%
Forecast & RatingHold
1analysts
- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
Target price forecast
Forecast dateOct 28, 2024
Forecast met0.0%
Stock price$0.58
Avg. target$40.0
High target$50
Low target$30
Analyst ratings
Strong buy
Buy
Hold
Sell
Strong sell
Source: S&P Global
This information is for reference only and is not investment advice.